Hepatitis C can be cured: will hepatitis B become next?


Cite item

Full Text

Abstract

Chronic hepatitis B (CHB) and C (CHC) are one of the leading causes of cirrhosis and liver cancer with over a million of people dying annually from their consequences. In Russia CHB and CHC morbidity and related mortality show an upward trend. As a result of recent breakthroughs in antiviral therapeutics CHC became a curable disease. Modern therapeutics effectively suppress viral replication in CHB patients, but withdrawal of antivirals usually results in disease relapse. Loss of HBsAg required for the so called «functional cure» is a very rare event. Moreover, «complete cure» when the virus is entirely eliminated from the body is not possible due to a persistent form of covalently closed circular DNA (cccDNA) of hepatitis B virus (HBV) in hepatocytes refractory to modern antivirals. Today, there is a plethora of new promising medications being at different stages of development that target different steps of viral life cycle, including inhibitors of interaction between HBV and its entry receptor NTCP, inhibitors of HBV cccDNA, inhibitors of nucleocapsid assembly, technologies of genome editing (TALENs, CRISPR/Cas etc) and RNA-interference. In addition to direct acting antivirals, there is a number of approaches aimed at enhancement of the innate and adaptive immune responses. In experimental conditions, some of these approaches or their combinations help to achieve functional cure. However, complete elimination of the virus is possible only using technologies of genome editing, capable of specific cccDNA degradation. Nuclease systems are currently at their early stages of development, and there is a long way to prove their efficacy and safety. Nevertheless, highly promising results of the recent years leave no doubt that CRISPR/Cas systems and similar technologies can become the basis of CHB therapy.

About the authors

V P Chulanov

ФБУН Центральный НИИ эпидемиологии Роспотребнадзора; ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России

Москва, Россия

A P Zueva

ФБУН Центральный НИИ эпидемиологии Роспотребнадзора; ФГБУ ВО «Московский государственный университет им. М.В. Ломоносова»

Москва, Россия

D S Kostyushev

ФБУН Центральный НИИ эпидемиологии Роспотребнадзора

Москва, Россия

S A Brezgin

ФБУН Центральный НИИ эпидемиологии Роспотребнадзора

Москва, Россия

E V Volchkova

ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России

Москва, Россия

V V Maleyev

ФБУН Центральный НИИ эпидемиологии Роспотребнадзора

Москва, Россия

References

  1. Global Hepatitis Report 2017. Geneva: World Health Organization; 2017.
  2. Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review. Ann Intern Med. 2017;166(9):637-648. https://doi.org/10.7326/M16-2575
  3. Bremer C, Glebe D. The Molecular Virology of Hepatitis B Virus. Seminars in Liver Disease. 2013;33(02):103-112. https://doi.org/10.1055/s-0033-1345717
  4. Habig J, Loeb D. Template Switches during Plus-Strand DNA Synthesis of Duck Hepatitis B Virus Are Influenced by the Base Composition of the Minus-Strand Terminal Redundancy. Journal of Virology. 2003;77(23):12412-12420. https://doi.org/10.1128/jvi.77.23.12412-12420.2003
  5. Yang H, Kao J. Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance. Emerging Microbes & Infections. 2014;3(9):e64. https://doi.org/10.1038/emi.2014.64
  6. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. Journal of Hepatology. 2005;42(3):302-308. https://doi.org/10.1016/j.jhep.2004.12.015
  7. Block T, Guo J. The Covalently Closed Circular Form of Hepatitis B Virus Genome: Is There Now an End in «Site»? Gastroenterology. 2016;150(1):34-36. https://doi.org/10.1053/j.gastro.2015.11.032
  8. Pollicino T, Belloni L, Raffa G et al. Hepatitis B Virus Replication Is Regulated by the Acetylation Status of Hepatitis B Virus cccDNA-Bound H3 and H4 Histones. Gastroenterology. 2006;130(3):823-837. https://doi.org/10.1053/j.gastro.2006.01.001
  9. Bock C, Schwinn S, Locarnini S et al. Structural organization of the hepatitis B virus minichromosome. Journal of Molecular Biology. 2001;307(1):183-196. https://doi.org/10.1006/jmbi.2000.4481
  10. Nassal M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut. 2015;64(12):1972-1984. https://doi.org/10.1136/gutjnl-2015-309809
  11. Vierling J. The Immunology of Hepatitis B. Clinics in Liver Disease. 2007;11(4):727-759. https://doi.org/10.1016/j.cld.2007.08.001
  12. Busca A, Kumar A. Innate immune responses in hepatitis B virus (HBV) infection. Virology Journal. 2014;11(1):22. https://doi.org/10.1186/1743-422x-11-22
  13. Chisari F, Isogawa M, Wieland. S. Pathogenesis of hepatitis B virus infection. Pathologie Biologie. 2010;58(4):258-266. https://doi.org/10.1016/j.patbio.2009.11.001
  14. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-398. https://doi.org/10.1016/j.jhep.2017.03.021
  15. Wang J, Shen T, Huang X et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. Journal of Hepatology. 2016;65(4):700-710. https://doi.org/10.1016/j.jhep.2016.05.029
  16. Liu S, Seto W, Lai C, Yuen M. Hepatitis B: treatment choice and monitoring for response and resistance. Expert Review of Gastroenterology & Hepatology. 2016;10(6):697-707. https://doi.org/10.1586/17474124.2016.1145547
  17. Wang Y-C, Yang S-S, Su C-W, et al. Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis. Scientific Reports. 2016;6:29605. https://doi.org/10.1038/srep29605
  18. Yan H, Li W. Sodium Taurocholate Cotransporting Polypeptide Acts as a Receptor for Hepatitis B and D Virus. Digestive Diseases. 2015;33(3):388-396. https://doi.org/10.1159/000371692
  19. Volz T, Allweiss L, ḾBarek M et al. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. Journal of Hepatology. 2013;58(5):861-867. https://doi.org/10.1016/j.jhep.2012.12.008
  20. Rizzo T, Urban S. Myrcludex B Therapy Reduced HBV DNA and HDV RNA in Phase 2a Clinical Trial. MD Conference Express. 2014;14(48):19-20. https://doi.org/10.1177/155989771448014
  21. Cai D, Mills C, Yu W et al. Identification of Disubstituted Sulfonamide Compounds as Specific Inhibitors of Hepatitis B Virus Covalently Closed Circular DNA Formation. Antimicrobial Agents and Chemotherapy. 2012;56(8):4277-4288. https://doi.org/10.1128/aac.00473-12
  22. Allweiss L, Dandri M. The Role of cccDNA in HBV Maintenance. Viruses. 2017;9(6):156. https://doi.org/10.3390/v9060156
  23. Kennedy E, Bassit L, Mueller H et al. Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. Virology. 2015;476: 196-205. https://doi.org/10.1016/j.virol.2014.12.001
  24. Dong C, Qu L, Wang H, Wei L, Dong Y, Xiong S. Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication. Antiviral Research. 2015;118:110-117. https://doi.org/10.1016/j.antiviral.2015.03.015
  25. Seeger C, Sohn J. Targeting Hepatitis B Virus With CRISPR/Cas9. Molecular Therapy — Nucleic Acids. 2014;3:e216. https://doi.org/10.1038/mtna.2014.68
  26. Lin S, Yang H, Kuo Y et al. The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo. Molecular Therapy — Nucleic Acids. 2014;3:e186. https://doi.org/10.1038/mtna.2014.38
  27. Wang J. Dual gRNAs guided CRISPR/Cas9 system inhibits hepatitis B virus replication. World Journal of Gastroenterology. 2015;21(32):9554. https://doi.org/10.3748/wjg.v21.i32.9554
  28. Zhen S, Hua L, Liu Y et al. Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus. Gene Therapy. 2015;22(5):404-412. https://doi.org/10.1038/gt.2015.2
  29. Liu X, Chen Y, Guo D, Chen S, Hao R. Inhibition of hepatitis B virus by the CRISPR/Cas9 system via targeting the conserved regions of the viral genome. Journal of General Virology. 2015;96(8):2252-2261. https://doi.org/10.1099/vir.0.000159
  30. Ramanan V, Shlomai A, Cox D et al. CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus. Scientific Reports. 2015;5(1). https://doi.org/10.1038/srep10833
  31. Karimova M, Beschorner N, Dammermann W et al. CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X. Scientific Reports. 2015;5(1). https://doi.org/10.1038/srep13734
  32. Yuen M.-F., Kim D.J., Weilert F. et al. NVR 3-778, a First-in-Class HBV Core Inhibitor, Alone and in Combination with Peg-Interferon (PegIFN), in Treatment-Naive HBeAg-Positive Patients: Early Reductions in HBV DNA and HBeAg. Journal of Hepatology. 2016;64(2):S210-S211. https://doi.org/10.1016/S0168-8278(16)00175-6
  33. Ren Q, Liu X, Luo Z, Li J, Wang C, Goldmann S, Zhang J, Zhang Y. Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4). Bioorg Med Chem. 2017;25(3):1042-1056. https://doi.org/10.1016/j.bmc.2016.12.017
  34. Huang Q, Mercier A, Zong Y et al. Preclinical Characterization of Potent Core Protein Assembly Modulators for the Treatment of Chronic Hepatitis B. Journal of Hepatology. 2017;64(2):S584. https://doi.org/10.1016/S0168-8278(16)01072-2
  35. Mani N, Cole AG, Ardzinski A et al. The HBV capsid inhibitor AB-423 exhibits a dual mode of action and displays additive/synergistic effects in in vitro combination studies. Hepatology. 2016; 64(1 Suppl):123A-124A. https://doi.org/10.1002/hep.28796
  36. Yang H, Kao J. Viral hepatitis: HBV cure — can we pin our hopes on immunotherapy? Nature Reviews Gastroenterology & Hepatology. 2015;12(3):129-131. https://doi.org/10.1038/nrgastro.2015.8
  37. Gish R, Yuen M, Chan H et al. Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent. Antiviral Research. 2015;121:97-108. https://doi.org/10.1016/j.antiviral.2015.06.019
  38. Thi EP, Ye X, Dhillon AP et al. Development of Second Generation RNA Interference Therapy for Hepatitis B Virus Infection. Hepatology. 2016;64(1,Suppl):922A. https://doi.org/10.1002/hep.28800
  39. Sepp-Lorenzino L, Sprague AG, Mayo T et al. GalNAc-siRNA conjugate ALN-HBV targets a highly conserved, pan-genotypic X-orf viral site and mediates profound and durable HBsAg silencing in vitro and in vivo. Hepatology. 2015;6(1?Suppl):224A-225A. https://doi.org/10.1002/hep.28171
  40. Lucifora J, Xia Y, Reisinger F. et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science. 2014;343:1221-1228. https://doi.org/10.1126/science.1243462
  41. Aderem A, Ulevitch R. Toll-like receptors in the induction of the innate immune response. Nature. 2000;406(6797):782-787. https://doi.org/10.1038/35021228
  42. Takeda K. Toll-like receptors in innate immunity. International Immunology. 2004;17(1):1-14. https://doi.org/10.1093/intimm/dxh186
  43. Funk E, Kottilil S, Gilliam B, Talwani R. Tickling the TLR7 to cure viral hepatitis. Journal of Translational Medicine. 2014;12(1):129. https://doi.org/10.1186/1479-5876-12-129
  44. Lanford R, Guerra B, Chavez D et al. GS-9620, an Oral Agonist of Toll-Like Receptor-7, Induces Prolonged Suppression of Hepatitis B Virus in Chronically Infected Chimpanzees. Gastroenterology. 2013;144(7):1508-1517.e10. https://doi.org/10.1053/j.gastro.2013.02.003
  45. Gane E, Lim Y, Gordon S et al. The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection. Journal of Hepatology. 2015;63(2):320-328. https://doi.org/10.1016/j.jhep.2015.02.037.
  46. Peng G, Luo B, Li J et al. Hepatitis B e-antigen Persistency is Associated with the Properties of HBV-Specific CD8 T Cells in CHB Patients. Journal of Clinical Immunology. 2010;31(2):195-204. https://doi.org/10.1007/s10875-010-9483-5
  47. Bengsch B, Martin B, Thimme R. Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation. Journal of Hepatology. 2014;61(6):1212-1219. https://doi.org/10.1016/j.jhep.2014.07.005

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies